Deborah Lowe, a 60-year-old from Milwaukee, filed a lawsuit after learning a feeding tube was left inside her body when she ...
The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.
Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.
Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...
Addresses the significant threat of antimicrobial resistance.
Forty percent of children undergoing CT for blunt abdominal trauma have incidental findings, but few require urgent care, a study finds.
Pharmaceutical Technology on MSN4d
FDA approves AbbVie’s Emblaveo for intra-abdominal infectionsAbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...
The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...
Hysterectomy is one of the most prevalent surgeries worldwide. Nine out of every ten hysterectomies are performed for noncancerous conditions that are not life threatening but have a negative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback